<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04290130</url>
  </required_header>
  <id_info>
    <org_study_id>844668</org_study_id>
    <nct_id>NCT04290130</nct_id>
  </id_info>
  <brief_title>Dynamic Neural Mechanisms of Audiovisual Speech Perception</brief_title>
  <official_title>Dynamic Neural Mechanisms of Audiovisual Speech Perception</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Baylor College of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Understanding speech is one of the most important functions of the human brain. We use&#xD;
      information from both the auditory modality (the voice the of person we are talking to) and&#xD;
      the visual modality (the facial movements of the person we are talking to) to understand&#xD;
      speech. We will use intracranial encephalography to study the organization and operation of&#xD;
      the brain during audiovisual speech perception.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">September 15, 2019</start_date>
  <completion_date type="Anticipated">May 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2024</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measurement of neural activity</measure>
    <time_frame>During the procedure.</time_frame>
    <description>The name of the measurement is the broadband high-frequency activity (BHA) in the brain in response to audiovisual speech. The unit of measure is % increase in power from pre-stimulus baseline. The name of the measurement tool is intracranial EEG, recordings of the raw voltage signal from each electrode implanted in the brain. The voltage-by-time signal will be converted to spectral space using a wavelet transform, and the magnitude of the power between 70 and 150 Hz inclusive in a time window between 0 ms and 500 ms after stimulus onset will be calculated.</description>
  </primary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Speech Perception</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Measurement of brain activity using electrodes.</intervention_name>
    <description>We will present audiovisual speech and record neural responses.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  must be undergoing neurosurgery for the treatment of a brain disorder&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  must have corrected-to-normal vision and hearing&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>February 25, 2020</study_first_submitted>
  <study_first_submitted_qc>February 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 28, 2020</study_first_posted>
  <last_update_submitted>July 2, 2021</last_update_submitted>
  <last_update_submitted_qc>July 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pennsylvania</investigator_affiliation>
    <investigator_full_name>Michael Beauchamp, PhD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

